Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Piyameth DilokthornsakulRatree SawangjitPisit TangkijvanichManeerat ChayanupatkulTawesak TanwandeeWattana SukeepaisarnjaroenPajaree SriutthaUnchalee PermsuwanPublished in: Applied health economics and health policy (2022)
At current prices, TAF, TDF, LAM/TAF, and LAM/TDF are dominant options, and ETV/TAF or ETV/TDF are cost-effective options. LAM/TAF is the most cost-effective option, followed by TAF.